Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women

C. Nappi; G. Colace; G. F. Di Renzo; M. Taglialatela; S. Amoroso; L. Annunziato; U. Montemagno

doi:10.1007/BF00637669

Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women

C. Nappi, G. Colace, G. F. Di Renzo, M. Taglialatela, S. Amoroso, L. Annunziato, U. Montemagno

IRCCS SDN

Research output: Contribution to journal › Article › peer-review

Abstract

In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.

Original language	English
Pages (from-to)	457-460
Number of pages	4
Journal	European Journal of Clinical Pharmacology
Volume	32
Issue number	5
DOIs	https://doi.org/10.1007/BF00637669
Publication status	Published - Sep 1987

Keywords

adverse effect
bromoergocriptine
domperidone
dopamine
prolactin
puerperal hyperprolactinaemia

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1007/BF00637669

Fingerprint Dive into the research topics of 'Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women'. Together they form a unique fingerprint.

Cite this

Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women. / Nappi, C.; Colace, G.; Di Renzo, G. F.; Taglialatela, M.; Amoroso, S.; Annunziato, L.; Montemagno, U.

In: European Journal of Clinical Pharmacology, Vol. 32, No. 5, 09.1987, p. 457-460.

Research output: Contribution to journal › Article › peer-review

@article{324ccf2f94d147de99e27bfda48e312d,

title = "Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women",

abstract = "In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.",

keywords = "adverse effect, bromoergocriptine, domperidone, dopamine, prolactin, puerperal hyperprolactinaemia",

author = "C. Nappi and G. Colace and {Di Renzo}, {G. F.} and M. Taglialatela and S. Amoroso and L. Annunziato and U. Montemagno",

year = "1987",

month = sep,

doi = "10.1007/BF00637669",

language = "English",

volume = "32",

pages = "457--460",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - Domperidone antagonizes bromoergocriptine - Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women

AU - Nappi, C.

AU - Colace, G.

AU - Di Renzo, G. F.

AU - Taglialatela, M.

AU - Amoroso, S.

AU - Annunziato, L.

AU - Montemagno, U.

PY - 1987/9

Y1 - 1987/9

N2 - In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.

AB - In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL - secreting cells of the anterior pituitary gland.

KW - adverse effect

KW - bromoergocriptine

KW - domperidone

KW - dopamine

KW - prolactin

KW - puerperal hyperprolactinaemia

UR - http://www.scopus.com/inward/record.url?scp=0023181376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023181376&partnerID=8YFLogxK

U2 - 10.1007/BF00637669

DO - 10.1007/BF00637669

M3 - Article

C2 - 3622595

AN - SCOPUS:0023181376

VL - 32

SP - 457

EP - 460

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -